On Friday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) opened lower -3.77% from the last session, before settling in for the closing price of $7.17. Price fluctuations for PHAT have ranged from $6.07 to $19.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -37.62% at the time writing. With a float of $34.87 million, this company’s outstanding shares have now reached $68.32 million.
The firm has a total of 452 workers. Let’s measure their productivity. In terms of profitability, gross margin is 85.02%, operating margin of -1096.02%, and the pretax margin is -1292.14%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Phathom Pharmaceuticals Inc is 49.01%, while institutional ownership is 68.89%. The most recent insider transaction that took place on Jan 21 ’25, was worth 43,371. In this transaction CFO and CBO of this company sold 6,583 shares at a rate of $6.59, taking the stock ownership to the 93,546 shares. Before that another transaction happened on Jan 21 ’25, when Company’s Chief Operating Officer sold 7,886 for $6.59, making the entire transaction worth $51,957. This insider now owns 233,390 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.66% during the next five years compared to -137.06% drop over the previous five years of trading.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Check out the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). In the past quarter, the stock posted a quick ratio of 5.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.69, a number that is poised to hit -1.21 in the next quarter and is forecasted to reach -4.12 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Analysing the last 5-days average volume posted by the [Phathom Pharmaceuticals Inc, PHAT], we can find that recorded value of 1.11 million was better than the volume posted last year of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 77.63%. Additionally, its Average True Range was 0.55.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 4.12%, which indicates a significant decrease from 35.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.79% in the past 14 days, which was lower than the 88.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.24, while its 200-day Moving Average is $11.89. Now, the first resistance to watch is $7.20. This is followed by the second major resistance level at $7.49. The third major resistance level sits at $7.74. If the price goes on to break the first support level at $6.66, it is likely to go to the next support level at $6.41. Should the price break the second support level, the third support level stands at $6.12.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are currently 68,377K shares outstanding in the company with a market cap of 471.80 million. Presently, the company’s annual sales total 680 K according to its annual income of -201,590 K. Last quarter, the company’s sales amounted to 16,350 K and its income totaled -85,580 K.
